Kinases as drug targets in the treatment of bipolar disorder

Drug Discovery Today

Volumn 13, Issue 7-8, 2008, Pages 295-302

  Catapano, Lisa A ^a   Manji, Husseini K ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; 2 (3 CHLORO 4 HYDROXYANILINO) 3 (2 NITROPHENYL)MALEIMIDE; AMPA RECEPTOR; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; AR A 014418; ATYPICAL ANTIPSYCHOTIC AGENT; DOPAMINE; GEFITINIB; GLUTAMIC ACID; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; IMATINIB; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; NEUROPEPTIDE; NEUROTRANSMITTER; NEUROTROPHIC FACTOR; PHOSPHOTRANSFERASE; PLACEBO; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; PSYCHOSTIMULANT AGENT; SEROTONIN; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID;

BIPOLAR DISORDER; CENTRAL NERVOUS SYSTEM DISEASE; CIRCADIAN RHYTHM; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; FEASIBILITY STUDY; HUMAN; MEDICAL INFORMATION; MEDICAL RESEARCH; MOOD; NEUROPROTECTION; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; THERAPY EFFECT;

ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; DRUG DELIVERY SYSTEMS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 40749155001     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2008.02.007     Document Type: Review

References (81)

1. Revicki D.A., et al. Bipolar disorder and health-related quality of life: review of burden of disease and clinical trials. Pharmacoeconomics 23 (2005) 583-594
2. Baum A.E., et al. A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Mol. Psychiatry 13 (2008) 197-207
3. Goodwin F.K., and Jamison K.R. Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression (2007), Oxford University Press
4. Woodgett J.R. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J. 9 (1990) 2431-2438
5. Gould T.D., and Manji H.K. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology 30 (2005) 1223-1237
6. Cohen P., and Frame S. The renaissance of GSK3. Nat. Rev. Mol. Cell Biol. 2 (2001) 769-776
7. Doble B.W., and Woodgett J.R. GSK-3: tricks of the trade for a multi-tasking kinase. J. Cell Sci. 116 (2003) 1175-1186
8. Gould T.D., et al. Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders. Curr. Drug Targets 7 (2006) 1399-1409
9. Gurvich N., and Klein P.S. Lithium and valproic acid: parallels and contrasts in diverse signaling contexts. Pharmacol. Therap. 96 (2002) 45-66
10. Hall A.C., et al. Axonal remodeling and synaptic differentiation in the cerebellum is regulated by WNT-7a signaling. Cell 100 (2000) 525-535
11. Huang H.C., and Klein P.S. Multiple roles for glycogen synthase kinase-3 as a drug target in Alzheimer's disease. Curr. Drug Targets 7 (2006) 1389-1397
12. Jope R.S., and Johnson S.L. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem. Sci. 29 (2004) 95-102
13. Salinas P.C. Wnt factors in axonal remodelling and synaptogenesis. Biochem. Soc. Symp. 65 (1999) 101-109
14. Shaltiel G., et al. Neurotrophic signaling cascades in the pathophysiology and treatment of bipolar disorder. Curr. Opin. Pharmacol. 7 (2007) 22-26
15. Gould T.D., and Manji H.K. The Wnt signaling pathway in bipolar disorder. Neuroscientist 8 (2002) 497-511
16. Li X., et al. Glycogen synthase kinase-3beta, mood stabilizers, and neuroprotection. Bipolar Disord. 4 (2002) 137-144
17. Klein P.S., and Melton D.A. A molecular mechanism for the effect of lithium on development. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 8455-8459
18. Martinez A., Castro A., and Medina M. Glycogen Synthase Kinase 3 (GSK-3) and Its Inhibitors (2006), John Wiley & Sons, Inc.
19. Chen G., et al. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J. Neurochem. 72 (1999) 1327-1330
20. Roh M.S., et al. Biphasic changes in the Ser-9 phosphorylation of glycogen synthase kinase-3beta after electroconvulsive shock in the rat brain. Prog. Neuropsychopharmacol. Biol. Psychiatry 27 (2003) 1-5
21. Gould T.D., et al. In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. Neuropsychopharmacology 29 (2004) 32-38
22. Hedgepeth C., et al. Activation of the Wnt signaling pathway: a molecular mechanism for lithium action. Develop. Biol. 185 (1997) 82-91
23. Hong M., et al. Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. J. Biol. Chem. 272 (1997) 25326-25332
24. Lovestone S., et al. Lithium reduces tau phosphorylation: effects in living cells and in neurons at therapeutic concentrations. Biol. Psychiatry 45 (1999) 995-1003
25. Munoz-Montano J.R., et al. Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons. FEBS Lett. 411 (1997) 183-188
26. Noble W., et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 6990-6995
27. O'Brien W.T., et al. Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium. J. Neurosci. 24 (2004) 6791-6798
28. Stambolic V., et al. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr. Biol. 6 (1996) 1664-1668
29. Moore G.J., et al. Lithium-induced increase in human brain grey matter. Lancet 356 (2000) 1241-1242
30. Bearden C.E., et al. Greater cortical gray matter density in lithium-treated patients with bipolar disorder. Biol. Psychiatry 62 (2007) 7-16
31. Yazlovitskaya E.M., et al. Lithium treatment prevents neurocognitive deficit resulting from cranial irradiation. Cancer Res. 66 (2006) 11179-11186
32. Manji H.K., and Lenox R.H. The nature of bipolar disorder. J. Clin. Psychiatry 61 Suppl. 13 (2000) 42-57
33. Huang X., et al. Support of retinal ganglion cell survival and axon regeneration by lithium through a Bcl-2-dependent mechanism. Invest. Ophthalmol. Vis. Sci. 44 (2003) 347-354
34. Lai J.S., et al. Cytoprotection by lithium and valproate varies between cell types and cellular stresses. Eur. J. Pharmacol. 539 (2006) 18-26
35. Bruno V., et al. Antidegenerative effects of Mg(2+)-valproate in cultured cerebellar neurons. Funct. Neurol. 10 (1995) 121-130
36. +. Eur. J. Biochem. 266 (1999) 886-891
37. Ren M., et al. Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J. Neurochem. 89 (2004) 1358-1367
38. Jope R.S., and Bijur G.N. Mood stabilizers, glycogen synthase kinase-3beta and cell survival. Mol. Psychiatry 7 Suppl. 1 (2002) S35-S45
39. Liang M.H., and Chuang D.M. Regulation and function of glycogen synthase kinase-3 isoforms in neuronal survival. J. Biol. Chem. 282 (2007) 3904-3917
40. Eickholt B.J., et al. An inactive pool of GSK-3 at the leading edge of growth cones is implicated in Semaphorin 3A signaling. J. Cell Biol. 157 (2002) 211-217
41. Sayas C.L., et al. The neurite retraction induced by lysophosphatidic acid increases Alzheimer's disease-like Tau phosphorylation. J. Biol. Chem. 274 (1999) 37046-37052
42. Jiang H., et al. Both the establishment and the maintenance of neuronal polarity require active mechanisms: critical roles of GSK-3beta and its upstream regulators. Cell 120 (2005) 123-135
43. Kim W.Y., et al. Essential roles for GSK-3s and GSK-3-primed substrates in neurotrophin-induced and hippocampal axon growth. Neuron 52 (2006) 981-996
44. Yoshimura T., et al. GSK-3beta regulates phosphorylation of CRMP-2 and neuronal polarity. Cell 120 (2005) 137-149
45. Du J., et al. Structurally dissimilar antimanic agents modulate synaptic plasticity by regulating AMPA glutamate receptor subunit GluR1 synaptic expression. Ann. N. Y. Acad. Sci. 1003 (2003) 378-380
46. Peineau S., et al. LTP inhibits LTD in the hippocampus via regulation of GSK3beta. Neuron 53 (2007) 703-717
47. Jope R.S., and Roh M.S. Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. Curr. Drug Targets 7 (2006) 1421-1434
48. Kaidanovich-Beilin O., et al. Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on beta-catenin in mouse hippocampus. Biol. Psychiatry 55 (2004) 781-784
49. Beaulieu J.M., et al. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 5099-5104
50. Gould T.D., et al. B-catenin overexpression in the mouse brain phenocopies lithium-sensitive behaviors. Neuropsychopharmacology 32 (2007) 2173-2183
51. Jackson A., et al. A systematic review of manic and depressive prodromes. J. Affect. Disord. 74 (2003) 209-217
52. Wehr T.A., et al. Sleep reduction as a final common pathway in the genesis of mania. Am. J. Psychiatry 144 (1987) 201-204
53. Benedetti F., et al. Influence of CLOCK gene polymorphism on circadian mood fluctuation and illness recurrence in bipolar depression. Am. J. Med. Genet. B Neuropsychiatr. Genet. 123 (2003) 23-26
54. Martinek S., et al. A role for the segment polarity gene shaggy/GSK-3 in the Drosophila circadian clock. Cell 105 (2001) 769-779
55. Kaladchibachi S.A., et al. Glycogen synthase kinase 3, circadian rhythms, and bipolar disorder: a molecular link in the therapeutic action of lithium. J. Circadian Rhythms 5 (2007) 3
56. Johnsson A., et al. Effect of lithium carbonate on circadian periodicity in humans. Pharmakopsychiatr. Neuropsychopharmakol. 12 (1979) 423-425
57. Iwahana E., et al. Effect of lithium on the circadian rhythms of locomotor activity and glycogen synthase kinase-3 protein expression in the mouse suprachiasmatic nuclei. Eur. J. Neurosci. 19 (2004) 2281-2287
58. Jolma I.W., et al. Lithium leads to an increased FRQ protein stability and to a partial loss of temperature compensation in the Neurospora circadian clock. J. Biol. Rhythms 21 (2006) 327-334
59. Kato T. Molecular genetics of bipolar disorder and depression. Psychiatry Clin. Neurosci. 61 (2007) 3-19
60. Phiel C.J., et al. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 423 (2003) 435-439
61. Hernandez F., and Avila J. GSK-3, a key player in Alzheimer's Disease. In: Martinez A., Castro A., and Medina M. (Eds). Glycogen Synthase Kinase 3 (GSK-3) and Its Inhibitors (2006), John Wiley & Sons. Inc. 107-124
62. Rockenstein E., et al. Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. J. Neurosci. 27 (2007) 1981-1991
63. Meijer L., et al. Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol. Sci. 25 (2004) 471-480
64. Facci L., and Skaper S.D. Glycogen synthase kinase 3: role in neurodegeneration and neuroprotection. In: Martinez A., Castro A., and Medina M. (Eds). Glycogen Synthase Kinase 3 (GSK-3) and Its Inhibitors (2006), John Wiley & Sons, Inc. 173-187
65. Gould T.D., et al. AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int. J. Neuropsychopharmacol. 7 (2004) 387-390
66. Conde S., et al. Thienyl and phenyl alpha-halomethyl ketones: new inhibitors of glycogen synthase kinase (GSK-3beta) from a library of compound searching. J. Med. Chem. 46 (2003) 4631-4633
67. Cohen P., and Goedert M. GSK3 inhibitors: development and therapeutic potential. Nat. Rev. Drug Discov. 3 (2004) 479-487
68. Hoeflich K.P., et al. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 406 (2000) 86-90
69. Kockeritz L., et al. Glycogen synthase kinase-3--an overview of an over-achieving protein kinase. Curr. Drug Targets 7 (2006) 1377-1388
70. Cohen Y., et al. Cancer morbidity in psychiatric patients: influence of lithium carbonate treatment. Med. Oncol. 15 (1998) 32-36
71. Serova M., et al. Preclinical and clinical development of novel agents that target the protein kinase C family. Semin. Oncol. 33 (2006) 466-478
72. Manji H.K., and Lenox R.H. Ziskind-Somerfeld Research Award. Protein kinase C signaling in the brain: molecular transduction of mood stabilization in the treatment of manic-depressive illness. Biol. Psychiatry 46 (1999) 1328-1351
73. Einat H., et al. Protein Kinase C Inhibition by Tamoxifen Antagonizes Manic-Like Behavior in Rats: Implications for the Development of Novel Therapeutics for Bipolar Disorder. Neuropsychobiology 55 (2007) 123-131
74. Birnbaum S.G., et al. Protein kinase C overactivity impairs prefrontal cortical regulation of working memory. Science 306 (2004) 882-884
75. Bebchuk J.M., et al. A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania. Arch. Gen. Psychiatry 57 (2000) 95-97
76. Zarate Jr. C.A., et al. Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord. 9 (2007) 561-570
77. The Wellcome Trust Case Control Consortium. (2007) Genome-wide association study of 14,000 cases of seven common diseases and 3000 shared controls. Nature 447, 661-678
78. Lee J.H., et al. A highly potent and selective PKCalpha inhibitor generated via combinatorial modification of a peptide scaffold. J. Am. Chem. Soc. 126 (2004) 3394-3395
79. Vlahos C.J., et al. Kinases as therapeutic targets for heart failure. Nat. Rev. Drug. Discov. 2 (2003) 99-113
80. Schloesser R.J., et al. Cellular Plasticity Cascades in the Pathophysiology and Treatment of Bipolar Disorder. Neuropsychopharmacology 33 (2007) 110-133
81. Coyle J.T., and Manji H.K. Getting balance: drugs for bipolar disorder share target. Nat. Med. 8 (2002) 557-558